TY4028

N/A

Report date: 2023/06/29 15:03:36
NME

Base Information

Drug NameTY4028
Drug Alias NameTY-4028TY4028
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsEGFR exon 20 insertion mutationsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTYK Medicines Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTYK Medicines Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A